Tonix Pharmaceuticals Completes Food Effect, Dosing Study of TNX-102 SL, Plans New Drug Application

Tonix Pharmaceuticals Completes Food Effect, Dosing Study of TNX-102 SL, Plans New Drug Application
Tonix Pharmaceuticals has finished the essential fed-fasting and dose proportionality tests of its TNX-102 SL investigational therapy in healthy volunteers. The data from these tests are expected to support a New Drug Application (NDA) of TNX-102 SL for the treatment of fibromyalgia (FM) and post traumatic stress disorder (PTSD), the company said in a press release. Tonix is currently recruiting patients for a Phase 3 trial, called RELIEF, testing the therapy in people with fibromyalgia (NCT04172831). Enrollment and U.S. test site information is available here. TNX-102 SL is a non-opioid, non-addictive analgesic, or pain killer, that acts on the central nervous system to reduce symptoms of pain. Currently, the investigational therapy has not been approved for any indication. Developed as a re
Subscribe or to access all post and page content.